aibioTG Therapeutics TGTX buyback news
Top story · Aug 3, 2026 · SEC filing 8-K
TG Therapeutics reports results
On August 3, 2026, the Company issued a press release announcing results of operations for the three and six months ended June 30, 2026.
- Ticker
- TGTX
- Listing
- NASDAQ, United States
- Next date
- Second half of 2026
- Chief executive
- Michael S. Weiss, Chairman and Chief Executive Officer
Desk view · Opinion · Updated Oct 22, 2026
TG's BRIUMVI is working. Subcutaneous dosing is the next bet
TG has a fast-growing, profitable MS drug and two line extensions that look likely to work. The company has added debt and spent heavily to prepare a subcutaneous version, so the phase 3 readout carries more weight than its low scientific risk suggests. Its early bets outside MS remain speculative.
Read the full desk viewaibio.space Investor Rank · Opinion
8/10 Positive view
BRIUMVI is profitable with U.S. sales up 64% and line extensions look likely to work, but it is a one-drug company carrying a $750 million term loan.
- Technology
- 2/2
- Odds
- 2/2
- Balance sheet
- 1/2
- Risk
- 1/2
- Momentum
- 2/2
Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. How the rank works.
- Technology
- Proven in market. BRIUMVI's seven-year data show 88.3% of continuously treated patients free of confirmed disability progression, and U.S. sales grew about 64% in Q2.
- Odds
- Low-risk extensions. ENHANCE met its bioequivalence endpoint, and modeled exposure for the subcutaneous phase 3 sits well above the non-inferiority bar, though azer-cel is still phase 1.
- Balance sheet
- Profitable with debt. TG held $612.3 million in cash and investments at June 30 against a $750 million term loan.
- Main risk
- One-drug company. Almost all revenue is BRIUMVI, and heavy subcutaneous manufacturing spending cut Q2 net income to $7.8 million.
- Watch next
- Subcutaneous phase 3. Topline data are due at year-end 2026 or in the first quarter of 2027.
Top news on TG
- Financings
TG Therapeutics raises BRIUMVI sales guidance and widens buyback to $300 million
First-quarter U.S. BRIUMVI sales rose 63% to $194.8 million. A $750 million Blue Owl loan in March funds growth and repurchases.
Questions investors ask
What is aibio.space's Investor Rank for TG Therapeutics?
8 out of 10, our positive view. BRIUMVI is profitable with U.S. sales up 64% and line extensions look likely to work, but it is a one-drug company carrying a $750 million term loan. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. Source
What is BRIUMVI?
BRIUMVI (ublituximab-xiiy) is TG Therapeutics' anti-CD20 antibody given by infusion for relapsing forms of multiple sclerosis in adults. It is glycoengineered to deplete B cells at low doses. Source
What is TG Therapeutics' 2026 revenue guidance?
In August 2026 TG raised its full-year targets to about $950 million in total global revenue and $890 million to $905 million in U.S. BRIUMVI net product revenue. Source
When will subcutaneous BRIUMVI phase 3 data come out?
TG expects topline phase 3 data at year-end 2026 or in the first quarter of 2027, and has pointed to a potential approval in 2028. Source
Is TG Therapeutics profitable?
Yes. TG reported net income of $7.8 million in the second quarter of 2026 and $27.6 million for the first half, though profit fell as subcutaneous manufacturing costs rose. Source
What is azer-cel?
Azer-cel is an allogeneic, off-the-shelf CD19-directed CAR-T cell therapy that TG is testing in a phase 1 study in progressive MS and B-cell mediated autoimmune disorders. Source
What is the latest TG Therapeutics (TGTX) stock news?
Our latest story on TG Therapeutics, dated May 6, 2026: "TG Therapeutics raises BRIUMVI sales guidance and widens buyback to $300 million". First-quarter U.S. BRIUMVI sales rose 63% to $194.8 million. A $750 million Blue Owl loan in March funds growth and repurchases. Source
What is TG Therapeutics's latest stock offering or financing news?
Our latest financing story, dated May 6, 2026: "TG Therapeutics raises BRIUMVI sales guidance and widens buyback to $300 million". First-quarter U.S. BRIUMVI sales rose 63% to $194.8 million. A $750 million Blue Owl loan in March funds growth and repurchases. Source
What is TG Therapeutics's market cap?
We do not publish live share prices. In its annual report, TG Therapeutics, Inc. put the market value of shares held by non-affiliates (public float) at $2.50 billion as of Jun 30, 2025. Source
Is TG Therapeutics a smaller reporting company?
SEC records list TG Therapeutics, Inc.'s filer category as: Large accelerated filer. Source
Where is TG Therapeutics headquartered?
SEC records list its business address as 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY, 10014. Source
When does TG Therapeutics's fiscal year end?
TG Therapeutics, Inc.'s fiscal year ends on December 31, per SEC records. Source
What did TG Therapeutics last file with the SEC?
Its most recent filing in our record is a 10-Q filed 2026-08-05. All of its filings are on SEC EDGAR. Source
What was TG Therapeutics called before?
SEC records list these former names: MANHATTAN PHARMACEUTICALS INC; ATLANTIC TECHNOLOGY VENTURES INC; ATLANTIC PHARMACEUTICALS INC. Source
What industry is TG Therapeutics in?
Its SEC industry code (SIC 2834) is Pharmaceutical Preparations. Source
Legal and investor matters
Part II, Item 1 of the 10-Q filed 2026-08-05 states: "We, and our subsidiaries, are not a party to, and our property is not the subject of, any material pending legal proceedings." Source
- Financing
TG Therapeutics establishes $750 million term loan with Blue Owl
On 2026-03-18 TG Therapeutics amended its financing agreement with Blue Owl Capital Corporation as administrative agent. The amendment set up a $750 million term loan, borrowed in full that day, and part of the proceeds repaid the initial term loans. It also created an uncommitted additional facility of up to $250 million. The 2026 term loan matures on 2031-03-18.
Pipeline
| Program | Indication | Stage |
|---|---|---|
| BRIUMVI (ublituximab-xiiy), IV | Relapsing multiple sclerosis | Marketed in the U.S.; sold ex-U.S. through Neuraxpharm Source |
| BRIUMVI single 600 mg initiation infusion (ENHANCE) | Relapsing multiple sclerosis | Phase 3 met primary endpoint; supplemental BLA targeted 2H 2026 Source |
| Subcutaneous ublituximab | Relapsing multiple sclerosis | Phase 3 fully enrolled; topline data year-end 2026 or Q1 2027 Source |
| Azer-cel (allogeneic CD19 CAR-T) | Progressive MS and B-cell mediated autoimmune disorders | Phase 1 Source |
| BRIUMVI | Myasthenia gravis (maintenance after efgartigimod induction) | Phase 2, potentially registration-directed Source |
| BRIUMVI | Treatment-resistant schizophrenia | Phase 2 Source |
Stock chart
SEC filings and registration
- SEC name
- Tg Therapeutics, Inc.
- CIK
- 1001316
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- TGTX (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Large accelerated filer
- Business address
- 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY, 10014
- Phone
- (212) 554-4484
- Shares outstanding
- 153,069,053 as of 2026-08-03 (10-Q filed 2026-08-05)
- Former names
- MANHATTAN PHARMACEUTICALS INC; ATLANTIC TECHNOLOGY VENTURES INC; ATLANTIC PHARMACEUTICALS INC
Recent filings
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction